Edwards Lifesciences (NYSE:EW) Releases FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 2.950-3.050 for the period, compared to the consensus earnings per share estimate of 3.010. The company issued revenue guidance of $6.6 billion-$6.9 billion, compared to the consensus revenue estimate of $6.7 billion. Edwards Lifesciences also updated its Q3 2026 guidance to 0.710-0.770 EPS.

Edwards Lifesciences Stock Down 0.9%

NYSE EW traded down $0.74 on Thursday, reaching $83.63. The stock had a trading volume of 6,726,014 shares, compared to its average volume of 4,876,617. The company has a market capitalization of $48.15 billion, a price-to-earnings ratio of 44.48, a P/E/G ratio of 2.12 and a beta of 0.86. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The business has a 50 day moving average price of $87.65 and a 200 day moving average price of $83.90.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts forecast that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday. Mizuho boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Finally, Barclays reaffirmed an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $98.95.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 45,577 shares of company stock worth $3,855,527. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC grew its holdings in Edwards Lifesciences by 0.9% during the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after buying an additional 136 shares in the last quarter. BOKF NA lifted its stake in Edwards Lifesciences by 9.8% during the 3rd quarter. BOKF NA now owns 2,214 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 198 shares in the last quarter. L2 Asset Management LLC boosted its holdings in Edwards Lifesciences by 6.8% during the 4th quarter. L2 Asset Management LLC now owns 3,121 shares of the medical research company’s stock worth $266,000 after acquiring an additional 198 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Edwards Lifesciences by 3.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 5,962 shares of the medical research company’s stock worth $514,000 after purchasing an additional 222 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in Edwards Lifesciences by 8.3% in the 3rd quarter. Larson Financial Group LLC now owns 2,948 shares of the medical research company’s stock valued at $229,000 after buying an additional 227 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.